Nystrand Rolf
Bio-TeQ Nystrand Consulting, Malmö, Sweden.
EDTNA ERCA J. 2002 Jul-Sep;28(3):127-9. doi: 10.1111/j.1755-6686.2002.tb00225.x.
In dialysis, machines intended for use in the treatment modes haemodiafiltration (HDF) and haemofiltration (HF) have been on the market about 10 years. These machines are equipped to be able to produce the substitution fluid to be used for direct infusion. In principle, this is done by using the reverse osmosis water of the clinic and mixing in concentrates as usual to form dialysis fluid. The dialysis fluid is then filtered in order to prepare it for use as substitution fluid. The volumes used when the substitution fluid is prepared on-line are usually 20-50 litres in HDF mode and 70-150 litres in HF mode. This means that a patient treated 3 times a week is exposed to a total volume of substitution fluid ranging from 3,000 litres to a maximum 23,000 litres a year. Where else in medicine do we see something coming close to this? Because of these large infusion volumes, the issue of endotoxin levels becomes as important as the issue of sterility.
在透析领域，用于血液透析滤过（HDF）和血液滤过（HF）治疗模式的机器已上市约10年。这些机器具备生产用于直接输注的置换液的能力。原则上，这是通过使用诊所的反渗透水并像往常一样混入浓缩液以形成透析液来实现的。然后对透析液进行过滤，以便将其制备成置换液使用。在HDF模式下在线制备置换液时使用的体积通常为20 - 50升，在HF模式下为70 - 150升。这意味着每周接受3次治疗的患者每年接触的置换液总体积在3000升至最大23000升之间。在医学的其他领域，我们在哪里还能看到接近这种情况的呢？由于这些输注量很大，内毒素水平问题与无菌问题变得同样重要。
